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Abstract
We previously described that betulinic acid (BetA), a
naturally occurring pentacyclic triterpenoid, induces
apoptosis in tumor cells through the mitochondrial
pathway. Here, for the first time, we provide evidence
that BetA cooperated with anticancer drugs to induce
apoptosis and to inhibit clonogenic survival of tumor
cells. Combined treatment with BetA and anticancer
drugs acted in concert to induce loss of mitochondrial
membrane potential and the release of cytochrome c
and Smac from mitochondria, resulting in activation of
caspases and apoptosis. Overexpression of Bcl-2,
which blocked mitochondrial perturbations, also in-
hibited the cooperative effect of BetA and anticancer
drugs, indicating that cooperative interaction involved
the mitochondrial pathway. Notably, cooperation of
BetA and anticancer drugs was found for various
cytotoxic compounds with different modes of action
(e.g., doxorubicin, cisplatin, Taxol, VP16, or actino-
mycin D). Importantly, BetA and anticancer drugs
cooperated to induce apoptosis in different tumor cell
lines, including p53 mutant cells, and also in primary
tumor cells, but not in human fibroblasts indicating
some tumor specificity. These findings indicate that
using BetA as sensitizer in chemotherapy-based
combination regimens may be a novel strategy to
enhance the efficacy of anticancer therapy, which
warrants further investigation.
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Introduction
Primary or acquired resistance of many tumors to estab-
lished treatment regimens still constitutes a major concern
in oncology [1]. Thus, attempts to improve the survival of
cancer patients largely depend on strategies to target tumor
cell resistance. Induction of apoptosis in cancer cells is a
key killing mechanism for most antitumor therapies includ-
ing chemotherapy, g-irradiation, immunotherapy, or cyto-
kines [2,3]. Apoptosis pathways may be initiated through
different entry sites, such as death receptors (receptor
pathway) or mitochondria (mitochondrial pathway), resulting
in activation of effector caspases [4]. The mitochondrial path-
way plays a crucial role in drug-induced apoptosis [5]. On induc-
tion of apoptosis, apoptogenic factors such as cytochrome c,
apoptosis-inducing factor (AIF), or second mitochondria-
derived activator of caspase (Smac)/DIABLO are released
from mitochondria into the cytosol [6]. Cytochrome c triggers
caspase-3 activation through formation of the cytochrome c/
Apaf-1/caspase-9–containing apoptosome complex, whereas
Smac/DIABLO promotes caspase activation by neutralizing the
inhibitory effects to inhibitor of apoptosis protein (IAP) [6].
Because most antitumor therapies including chemotherapy
primarily act by inducing apoptosis in cancer cells, defects in
apoptosis programs may cause resistance [2,7]. Combination
treatment may prove to be advantageous in malignancies that
still partially respond to either treatment alone because they
may help to amplify weaker death signals. Thus, combination
therapies may constitute a potent strategy for bypassing
resistance. Betulinic acid (BetA) is a naturally occurring pen-
tacyclic triterpenoid derived from white birch trees, which
induces apoptosis in a variety of tumor cells [8–10]. We
previously found that BetA-induced apoptosis differs from
anticancer agents such as doxorubicin because BetA-induced
apoptosis is not associated with activation of ligand/receptor
systems such as CD95 and does not involve p53 [11]. In
BetA-induced apoptosis, perturbation of mitochondrial func-
tion, including loss of mitochondrial permeability transition,
precedes other key features of apoptosis such as activation
of the caspase cascade and nuclear fragmentation [12]. In
search for novel strategies to enhance the efficacy of antican-
cer therapy, we asked whether or not triggering the mitochon-
drial pathway by BetA would modulate the sensitivity of tumor
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cells for anticancer drug–induced apoptosis. Here, for the
first time, we provide evidence that combined treatment with




SHEP neuroblastoma cells, SHEP neuroblastoma cells
transfected with vector control (Neo) or Bcl-2, medulloblas-
toma (Daoy, p53 mutant), glioblastoma (A172), melanoma
(Mel-Juso) cells, or primary renal cell carcinoma cells
obtained from a patient with metastatic renal cell carcinoma
were maintained in RPMI 1640 or DMEM medium (Life
Technologies, Inc., Eggenstein, Germany) as previously
described [13]. Human fibroblasts (PromoCell, Heidelberg,
Germany) were maintained according to the manufacturer’s
instructions. A total of 0.5  105 cells/ml were cultured in
96-well, 24-well, or 6-well plates or in 75-cm2 flasks (Falcon,
Heidelberg, Germany).
Determination of Apoptosis, Cell Viability, and
Clonogenic Growth
Cells were incubated with BetA (BioService Halle GmbH,
Halle, Germany), doxorubicin, VP16, cisplatin, Taxol (all from
Sigma, Deisenhofen, Germany), or benzyloxycarbonyl-
Val-Ala-Asp-fluoromethylketone (zVAD.fmk; Bachem, Hei-
delberg, Germany) at indicated concentrations and times.
Apoptosis of adherent and detached cells was assessed by
fluorescence-activated cell sorting (FACS) analysis of DNA
fragmentation of propidium iodide–stained nuclei in permea-
bilized cells as previously described [13,14]. Cell viability was
determined by MTT assay according to the manufacturer’s
instructions (Roche Diagnostics, Mannheim, Germany). Clo-
nogenic growth was assessed by crystal violet staining as
previously described [15].
Western Blot Analysis
Western blot analyses were performed as previously
described [15], using mouse anti–caspase-8 monoclonal
antibody C15 (1:10 dilution of hybridoma supernatant; kindly
provided by P. Krammer), mouse anti–caspase-3 mono-
clonal antibody (1:1000; BD Biosciences, Heidelberg, Ger-
many), mouse anti-XIAP monoclonal antibody (1:1000,
H62120; BD Biosciences), mouse anti–cytochrome cmono-
clonal antibody (1:1000; BD Biosciences), rabbit anti-Smac
polyclonal antibody (1:1000; Calbiochem, Bad Soden,
Germany), and b-actin monoclonal antibody (1:10000;
Sigma), followed by goat antimouse IgG or goat antirabbit
IgG (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA).
Enhanced chemiluminescence (ECL; Amersham Pharma-
cia, Freiburg, Germany) was used for detection. Expression
of b-actin was used to control for equal gel loading.
Assessment of Caspase Activity
Caspase activity was determined by fluorogenic sub-
strates for caspase-3, caspase-8, or caspase-9 according
to the manufacturer’s instructions (caspase-3, Roche; cas-
pase-8, BioCat GmbH, Palo Alto, CA; caspase-9, Bachem).
Caspase activity was measured fluorometrically at 535 or
505 nm on a microplate fluorescence reader (1420 Victor
Multilabel Counter; Wallac, Rodgau-Jugesheim, Germany).
Preparation of Mitochondria or Cytosolic Extracts
Preparation of mitochondria or cytosolic extracts was
performed using the ApoAlert cell fractionation kit (BD Bio-
sciences) according to the manufacturer’s instructions.
Assessment of Mitochondrial Transmembrane Potential
or Cytochrome c Release
The cationic lipophilic fluorochrome chloromethyl-X-
rosamin (CMXRos) (1 mM; Molecular Probes, Eugene,
OR) was used to measure the mitochondrial transmem-
brane potential (DWm) [16]. Cells were incubated for
15 minutes at 37jC in the presence of fluorochrome,
washed in PBS/1% fetal calf serum (FCS), and immediately
analyzed by flow cytometry (FACScan; Becton Dickinson,
Heidelberg, Germany). CMXRos was recorded in fluores-
cence 3. Cytochrome c release was determined in permea-
bilized cells using anti–cytochrome c monoclonal antibody
(BD Biosciences) as previously described [17].
Results
BetA and Anticancer Drugs Cooperate to Induce Apoptosis
in Tumor Cells
In search for novel strategies to enhance the efficacy of
chemotherapy, we investigated the effect of the mitochon-
driotropic natural compound, BetA, on anticancer drug–
induced apoptosis. For these studies, we selected SHEP
neuroblastoma cells, which have previously been proven
suitable for studies on apoptosis pathways by our group
and other investigators [11,18]. Treatment of SHEP neuro-
blastoma cells with relatively low doses of either BetA or
doxorubicin alone induced only minimal apoptosis (Figure 1,
A and B). Interestingly, the combined treatment with BetA,
together with doxorubicin, cooperated to induce apoptosis
in SHEP neuroblastoma cells in a dose- and time-
dependent manner, as determined by analysis of DNA frag-
mentation (Figure 1, A and B). Similar results were
obtained when apoptosis was assessed by Annexin V
staining (data not shown). To see whether the combination
treatment with BetA and doxorubicin simply delayed cell
death or inhibited clonogenic survival of tumor cells, we
performed clonogenic assays. Importantly, BetA cooper-
ated with doxorubicin to reduce clonogenic survival of
tumor cells (Figure 2). To exclude that the sensitization
effect of BetA was restricted to doxorubicin, we tested BetA
in combinations of various anticancer drugs with different
modes of action. Also, BetA sensitized SHEP neuroblasto-
ma cells for apoptosis in response to treatment with VP16,
Taxol, or actinomycin D (Figure 3). We then extended our
studies to additional human cancer cell lines, which were
Cooperation of Betulinic Acid and Anticancer Drugs Fulda and Debatin 163
Neoplasia . Vol. 7, No. 2, 2005
previously found to respond to BetA [8,11], to exclude that
the cooperative effect of BetA and anticancer drugs was
restricted to a particular cell line. Importantly, BetA sensi-
tized medulloblastoma, glioblastoma, or melanoma cells for
anticancer drug–induced apoptosis (Figure 4A). Further-
more, we studied the effect of BetA on primary tumor cells
derived from metastatic renal cell carcinoma. Interestingly,
we found that BetA sensitized primary renal cell carcinoma
cells for doxorubicin- or cisplatinum-induced apoptosis
(Figure 4B). In contrast, BetA failed to sensitize untrans-
formed human fibroblasts for doxorubicin-induced apopto-
sis indicating some tumor specificity (Figure 4A). Together,
this set of experiments indicates that BetA cooperated with
anticancer drugs to trigger apoptosis in different human
tumor cell lines and primary tumor cells.
Beta and Anticancer Drugs Cooperate to Activate Caspases
To see whether apoptosis on treatment with BetA and
anticancer drugs required caspase activation, we used the
broad-range caspase inhibitor, zVAD.fmk. Apoptosis in re-
sponse to treatment with BetA and doxorubicin or VP16 was
almost completely blocked in the presence of zVAD.fmk,
demonstrating that apoptosis was mediated by activation of
caspases (Figure 5A). We then monitored caspase activa-
tion by Western blot analysis to see whether and at what
level of the caspase cascade BetA- and cytotoxic drug–
induced signaling pathways converged. Notably, the com-
bined treatment with BetA and doxorubicin cooperated to
activate caspase-8, caspase-3, and PARP (Figure 5B), in
line with our previous findings that BetA triggers activation of
caspase-3 or caspase-8 downstream of mitochondria [12].
Also, cleavage—and thus inactivation—of XIAP, an endoge-
nous caspase inhibitor, was only observed on combination
treatment with BetA and doxorubicin (Figure 5B). To directly
assess caspase activity, we also performed an enzymatic
caspase assay using fluorogenic caspase substrates.
Cotreatment with BetA and doxorubicin or VP16 resulted in
increased activity of caspase-3, caspase-9, and caspase-
8 compared to either treatment alone (Figure 6). Together,
this set of experiments demonstrates that BetA and antican-
cer drugs cooperated to activate caspases.
BetA and Anticancer Drugs Cooperate to Perturb
Mitochondrial Functions
We next analyzed the effect of BetA and anticancer
drugs on mitochondrial function because we previously
found that BetA triggers mitochondrial perturbations [11].
Combined treatment with BetA and doxorubicin or VP16
Figure 2. Cooperation of BetA and anticancer drugs to inhibit clonogenic
survival. SHEP neuroblastoma cells were treated with 0.1 g/ml VP16 (white
bars) or 0.01 g/ml doxorubicin (hatched bars) and/or 3 g/ml BetA.
Clonogenic survival was assessed by crystal violet staining after 7 days,
and colony numbers per well of a 24-well plate are indicated. Mean and SD of
triplicates are shown; similar results were obtained from three independent
experiments.
Figure 1. Cooperation of BetA and doxorubicin to induce apoptosis. SHEP
neuroblastoma cells were treated for 24 hours (A) or 48 hours (B) with BetA
(0 g/ml: white bars; 3 g/ml: vertically hatched bars; 4 g/ml: horizontally
hatched bars; 5 g/ml: black bars) and/or 0 to 0.2 g/ml doxorubicin.
Apoptosis was determined by FACS analysis of DNA fragmentation of
propidium iodide–stained nuclei. Mean and SD of triplicates are shown;
similar results were obtained from three independent experiments.
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resulted in enhanced breakdown of mitochondrial mem-
brane potential (MMP) compared to either treatment alone
(Figure 7). To further address the role of mitochondria in
BetA- and anticancer drug–induced apoptosis, we deter-
mined the release of cytochrome c from mitochondria by
flow cytometry, staining cytochrome c in permeabilized
cells. BetA and doxorubicin or VP16 acted in concert to
trigger cytochrome c release from mitochondria compared
to either treatment alone (Figure 8). Interestingly, loss of
MMP induced by combined treatment with BetA and
doxorubicin or VP16 preceded release of cytochrome c
from mitochondria. In addition, we analyzed the transloca-
tion of mitochondrial proteins into the cytosol by Western
blot analysis of mitochondrial and cytosolic cell fractions.
Figure 4. Cooperation of BetA and doxorubicin to induce apoptosis in human
tumor cell lines and primary tumor cells. (A) Cooperation of BetA and
doxorubicin to induce apoptosis in human tumor cell lines. Daoy medullo-
blastoma, A172 glioblastoma, Mel-Juso melanoma cells, or human fibroblasts
were treated for 24 hours with 5 g/ml BetA and/or 0.2 g/ml doxorubicin.
Apoptosis was determined by FACS analysis of DNA fragmentation of
propidium iodide–stained nuclei. Mean and SD of triplicates are shown;
similar results were obtained from three independent experiments. (B)
Cooperation of BetA and anticancer drugs to induce apoptosis in primary
renal cell carcinoma cells. Primary renal cell carcinoma cells were treated for
4 days with 2 g/ml doxorubicin (Dox-2), 0.6 g/ml doxorubicin (Dox-0.6), or
10 g/ml cisplatin (Cis-10) in the presence (black bars) or absence (white
bars) of 5 g/ml BetA. Cell survival was assessed by MTT assay. Percentage
of cell viability was determined as: (survival of treated cells  100 / survival
of untreated cells). Mean and SD of triplicates are shown; similar results were
obtained in two independent experiments.
Figure 3. Cooperation of BetA and anticancer drugs to induce apoptosis.
SHEP neuroblastoma cells were treated for 24 hours with 0 to 3 g/ml VP16
(A), 0 to 10 nM Taxol (B), or 0 to 10 ng/ml actinomycin D (C) in the presence
(black bars) or absence (white bars) of 5 g/ml BetA. Apoptosis was
determined by FACS analysis of DNA fragmentation of propidium iodide–
stained nuclei. Mean and SD of triplicates are shown; similar results were
obtained from three independent experiments.
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Increased release of cytochrome c and Smac from mito-
chondria into the cytosol was observed in cells treated with
BetA and doxorubicin compared to cells treated with BetA
or doxorubicin alone (Figure 9). To test whether loss of
MMP and cytochrome c release on treatment with BetA
and anticancer drugs required caspase activity, we used
the broad-range caspase inhibitor, zVAD.fmk. Interestingly,
loss of MMP and cytochrome c release following treatment
with BetA alone or with the combination of BetA and
doxorubicin or VP16, were markedly reduced in the pres-
ence of zVAD.fmk (Figure 10). This indicates that loss of
MMP and cytochrome c release on combined treatment
with BetA and anticancer drugs involved caspase-
dependent and also caspase-independent mechanisms.
Overexpression of Bcl-2 Inhibits Apoptosis Induced by BetA
and Anticancer Drugs
To further investigate whether the cooperative effect of
BetA and anticancer drugs was mediated by mitochondrial
perturbations, we used SHEP neuroblastoma cells in which
the mitochondrial pathway was blocked by Bcl-2 overexpres-
sion. Overexpression of Bcl-2 inhibited loss of MMP following
treatment with BetA, with doxorubicin or VP16, or with the
combination of BetA and doxorubicin or VP16 (Figure 11).
Also, overexpression of Bcl-2 inhibited the release of cyto-
chrome c frommitochondria upon treatment with BetA and/or
doxorubicin or VP16 (Figure 11). Importantly, overexpres-
sion of Bcl-2 also inhibited apoptosis in response to BetA and
doxorubicin (Figure 12). This indicates that the cooperative
effect of BetA and anticancer drugs was mediated through
the mitochondrial pathway.
Discussion
Because resistance of many tumors to established treat-
ment regimens still constitutes a major problem in cancer
therapy, novel strategies to target tumor cell resistance are
essential to improve patient outcome [1]. Most antitumor
therapies including chemotherapy, g-irradiation, immuno-
therapy, or cytokines primarily act by inducing apoptosis in
target cells, and defects in apoptosis programs may cause
resistance [2]. We previously found that BetA, a natural
compound derived from white birch trees, induces apoptosis
in tumor cells by directly triggering the mitochondrial path-
way of apoptosis [11]. Importantly, BetA-induced apoptosis
differs from apoptosis in response to treatment with anti-
cancer agents such as doxorubicin because BetA-induced
apoptosis does not involve p53 and is not associated with
activation of ligand/receptor systems such as CD95 [11]. In
the present study, we investigated whether or not activation
of the mitochondrial pathway by BetA would modulate the
sensitivity of tumor cells for anticancer drug–induced apo-
ptosis. Here, for the first time, we provide evidence that
combined treatment with BetA and anticancer drugs coop-
erated to induce apoptosis and to inhibit clonogenic survival
of tumor cells.
Simultaneous treatment with BetA and anticancer drugs
acted in concert to trigger loss of MMP and translocation
of cytochrome c and Smac from mitochondria into the
cytosol, resulting in activation of caspases, cleavage of
endogenous caspase inhibitors such as XIAP, and cell
Figure 5. Cooperation of BetA and anticancer drugs to activate caspases.
(A) Effect of caspase inhibition on BetA and anticancer drug– induced
apoptosis. SHEP neuroblastoma cells were treated for 24 hours with 5 g/ml
BetA and/or 0.2 g/ml doxorubicin and/or 3 g/ml VP16 in the presence or
absence of 50 M zVAD.fmk. Apoptosis was determined by FACS analysis
of DNA fragmentation of propidium iodide–stained nuclei. Mean and SD of
triplicates are shown; similar results were obtained from three independent
experiments. (B) Cooperation of BetA and doxorubicin to activate caspases.
SHEP neuroblastoma cells were treated for 2 to 24 hours with 5 g/ml BetA
and/or 0.2 g/ml doxorubicin. Expression of caspase-3, caspase-8, PARP,
XIAP, and -actin was assessed by Western blot analysis. Cleavage
products are indicated by arrows and nonspecific immune-reactive bands
are indicated by asterisk. A representative experiment out of three
independent experiments is shown.
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death. In contrast, single-agent treatment with suboptimal
concentrations of BetA or various anticancer drugs in-
duced only minimal mitochondrial alterations and minimal
activation of caspases. Interestingly, loss of MMP and
cytochrome c release on combined treatment with BetA
and anticancer drugs involved caspase-dependent and
also caspase-independent mechanisms. Although recent
studies have implicated caspase-2 in the mitochondrial
changes induced by cytotoxic agents in some cell lines
[19], we found no detectable caspase-2 activation by
Western blot analysis on combined treatment with BetA
and anticancer drugs (data not shown). Because caspase-
3 has been reported to feed back to damage mitochondria,
enhanced caspase-3 activity on treatment with BetA and
anticancer drugs may act back on mitochondria in an
amplification loop. In addition, BetA may lower mitochond-
rially derived energy production and reduce repair follow-
ing anticancer drug treatment, which may contribute to its
sensitizing effect for anticancer agents. Importantly, com-
bination treatment with BetA and anticancer drugs not
simply delayed tumor growth, but inhibited clonogenic
survival of tumor cells. Notably, the cooperation effect of
BetA and anticancer drugs was found for a variety of
cytotoxic compounds with different modes of action, in-
cluding VP16, doxorubicin, cisplatin, Taxol, or actinomycin
D. Thus, lowering the threshold for apoptosis induction by
BetA can sensitize for apoptosis induced by various anti-
cancer drugs, as most anticancer drugs predominantly act
Figure 7. Cooperation of BetA and anticancer drugs to induce loss of MMP.
SHEP neuroblastoma cells were treated for 12 hours (A) or 24 hours (B) with
5 g/ml BetA and/or 0.2 g/ml doxorubicin and/or 3 g/ml VP16. MMP was
assessed by flow cytometry using the fluorescent dye, CMXRos. Mean and
SD of triplicates are shown; similar results were obtained from three in-
dependent experiments.
Figure 6. Cooperation of BetA and anticancer drugs to induce caspase
activity. SHEP neuroblastoma cells were treated for 24 hours with 5 g/ml
BetA and/or 0.2 g/ml doxorubicin and/or 3 g/ml VP16. Activity of caspase-3
(A), caspase-8 (B), or caspase-9 (C) was determined by enzymatic assay
using fluorogenic caspase substrates as described in Materials and Methods
section. X-fold increase in caspase activity compared to untreated controls is
shown. Mean and SD of triplicates are shown; similar results were obtained
from three independent experiments.
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by triggering a common pathway of apoptosis in tumor
cells. Importantly, the combination treatment with BetA and
anticancer drugs cooperated to induce apoptosis in differ-
ent tumor cell lines including p53 mutant cells (Daoy
medulloblastoma cells). Also, BetA enhanced the sensitiv-
ity of primary tumor cells for anticancer drug–induced
apoptosis. In contrast, BetA did not increase the sensitivity
of untransformed human fibroblast for drug-induced apo-
ptosis indicating some tumor specificity. To this end, we
and other investigators have previously reported that BetA
exerts selective cytotoxicity on tumor cell lines, but not on
normal human cells [10,20]. BetA has been shown to
trigger caspase-dependent apoptosis in a variety of tumor
cells, in particular in neuroectodermal tumor cells, although
caspase-independent cell death in response to BetA has
also been described [8,9,11,21]. Also, BetA was found to
act in concert with ionizing radiation, although the under-
lying mechanism has not exactly been defined [22].
By demonstrating that BetA can sensitize cancer cells
for anticancer drug treatment, our findings may have sev-
eral implications (e.g., for the proposed use of BetA in
cancer therapy). Although pharmacokinetic data for BetA
are limited at present, they indicate that pharmacologically
active plasma levels may be achieved in rodents after
systemic administration [23]. Because BetA significantly
potentiated the antitumor activity of cytotoxic drugs, BetA
may be used as a ‘‘sensitizer’’ in chemotherapy-based
regimens to enhance the efficacy of anticancer agents for
inhibition of tumor growth. Thus, the potential of BetA for
anticancer therapy may particularly reside in its ability to
Figure 9. Cooperation of BetA and doxorubicin to induce release of
mitochondrial proteins. SHEP neuroblastoma cells were treated for 24 hours
with 5 g/ml BetA and/or 0.2 g/ml doxorubicin. Expression of Smac,
cytochrome c, or COX4 in the mitochondrial (M) or cytosolic (C) fraction was
assessed by Western blot analysis. A representative experiment out of three
independent experiments is shown.
Figure 10. Effect of caspase inhibition on BetA and anticancer drug– induced
loss of MMP and cytochrome c release. SHEP neuroblastoma cells were
treated for 24 hourswith 5g/ml BetA and/or 0.2g/ml doxorubicin and/or 3g/
ml VP16 in the presence of 50 M zVAD.fmk. In (A), MMP was assessed
by flow cytometry using the fluorescent dye, CMXRos. In (B), release of
cytochrome c from mitochondria was assessed by flow cytometry, staining
cytochrome c in permeabilized cells as described in Materials and Methods
section. Mean and SD of triplicates are shown; similar results were obtained
from three independent experiments.
Figure 8. Cooperation of BetA and anticancer drugs to induce cytochrome c
release. SHEP neuroblastoma cells were treated for 12 hours (A) or 24 hours
(B) with 5 g/ml BetA and/or 0.2 g/ml doxorubicin and/or 3 g/ml VP16.
Release of cytochrome c from mitochondria was assessed by flow cytometry,
staining cytochrome c in permeabilized cells as described in Materials and
Methods section. Mean and SD of triplicates are shown; similar results were
obtained from three independent experiments.
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sensitize tumor cells for death induction or even to over-
come resistance. The rationale for combination therapies is
based on the concept that triggering tumor cell apoptosis
through distinct compounds may help to amplify weaker
death signals and ensure that apoptosis occurs within a
certain time frame. Thus, combination treatments may
prove to be advantageous in malignancies that still partially
respond to either treatment alone because they potentially
diminish the pool of tumor cells that give rise to an out-
growing resistant variant of the parental tumor and may
therefore constitute a potent strategy for bypassing resis-
tance. Also, combination treatment using low doses of each
agent may be advantageous in light of the fact that high
concentrations found to be active in vitro may often not
be achieved in vivo. Clinically, resistance to apoptosis is a
major cause of primary or acquired nonresponsiveness of
cancers leading to treatment failure. Thus, the combination
of BetA and anticancer drugs may be a novel strategy to
enhance the efficacy of chemotherapy-based regimens,
which warrants further investigation.
Figure 11. Effect of Bcl-2 overexpression on BetA and anticancer drug– induced mitochondrial perturbations. (A and B) Effect of Bcl-2 overexpression on BetA and
anticancer drug– induced loss of MMP. SHEP neuroblastoma cells transfected with vector control (A) or Bcl-2 (B) were treated for 24 hours with 5 g/ml BetA and/
or 0.2 g/ml doxorubicin and/or 3 g/ml VP16. MMP was assessed by flow cytometry using the fluorescent dye, CMXRos. Mean and SD of triplicates are shown;
similar results were obtained from three independent experiments. (C and D) Effect of Bcl-2 overexpression on BetA and drug-induced cytochrome c release.
SHEP neuroblastoma cells transfected with vector control (C) or Bcl-2 (D) were treated for 24 hours with 5 g/ml BetA and/or 0.2 g/ml doxorubicin and/or 3 g/ml
VP16. Release of cytochrome c from mitochondria was assessed by flow cytometry, staining cytochrome c in permeabilized cells as described in Materials and
Methods section. Mean and SD of triplicates are shown; similar results were obtained from three independent experiments.
Cooperation of Betulinic Acid and Anticancer Drugs Fulda and Debatin 169
Neoplasia . Vol. 7, No. 2, 2005
Acknowledgements
We thank P.H. Krammer (Heidelberg, Germany) for anti–
caspase-8 antibody and Petra Miller-Rostek for expert
technical assistance.
References
[1] Peto J (2001). Cancer epidemiology in the last century and the next
decade. Nature 411, 390–395.
[2] Herr I and Debatin KM (2001). Cellular stress response and apoptosis
in cancer therapy. Blood 98, 2603–2614.
[3] Lowe SW and Lin AW (2000). Apoptosis in cancer. Carcinogenesis
21, 485–495.
[4] Hengartner MO (2000). The biochemistry of apoptosis. Nature 407,
770–776.
[5] Debatin KM, Poncet D, and Kroemer G (2002). Chemotherapy: target-
ing the mitochondrial cell death pathway. Oncogene 21, 8786–8803.
[6] van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ, and
Vandenabeele P (2002). The role of mitochondrial factors in apoptosis:
a Russian roulette with more than one bullet. Cell Death Differ 9,
1031–1042.
[7] Johnstone RW, Ruefli AA, and Lowe SW (2002). Apoptosis: a link
between cancer genetics and chemotherapy. Cell 108, 153–164.
[8] Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA,
Beecher CW, Fong HH, Kinghorn AD, Brown DM, et al. (1995). Dis-
covery of betulinic acid as a selective inhibitor of human melanoma that
functions by induction of apoptosis. Nat Med 1, 1046–1051.
[9] Fulda S, Jeremias I, Pietsch T, and Debatin KM (1999). Betulinic acid: a
new chemotherapeutic agent in the treatment of neuroectodermal tu-
mors. Klin Padiatr 211, 319–322.
[10] Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-
Passerini C, and Formelli F (2002). Selective cytotoxicity of betulinic
acid on tumor cell lines, but not on normal cells. Cancer Lett 175,
17–25.
[11] Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez
G, Krammer G, Peter ME, and Debatin KM (1997). Betulinic acid
triggers CD95 (APO-1/Fas) – and p53-independent apoptosis via ac-
tivation of caspases in neuroectodermal tumors. Cancer Res 57,
4956–4964.
[12] Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, and
Debatin KM (1998). Activation of mitochondria and release of mito-
chondrial apoptogenic factors by betulinic acid. J Biol Chem 273,
33942–33948.
[13] Fulda S, Sieverts H, Friesen C, Herr I, and Debatin KM (1997). The
CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuro-
blastoma cells. Cancer Res 57, 3823–3829.
[14] Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, and Riccardi C
(1991). A rapid and simple method for measuring thymocyte apoptosis
by propidium iodide staining and flow cytometry. J Immunol Methods
139, 271–279.
[15] Fulda S and Debatin KM (2004). Sensitization for tumor necrosis
factor – related apoptosis-inducing ligand-induced apoptosis by the
chemopreventive agent resveratrol. Cancer Res 64, 337–346.
[16] Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, and Kroemer G
(2002). Quantitation of mitochondrial alterations associated with apo-
ptosis. J Immunol Methods 265, 39–47.
[17] Stahnke K, Eckhoff S, Mohr A, Meyer LH, and Debatin KM (2003).
Apoptosis induction in peripheral leukemia cells by remission induction
treatment in vivo: selective depletion and apoptosis in a CD34+ sub-
population of leukemia cells. Leukemia 17, 2130–2139.
[18] Kim B and Feldman EL (2002). Insulin-like growth factor I prevents
mannitol-induced degradation of focal adhesion kinase and akt. J Biol
Chem 277, 27393–27400.
[19] Lassus P, Opitz-Araya X, and Lazebnik Y (2002). Requirement for
caspase-2 in stress-induced apoptosis before mitochondrial permeabi-
lization. Science 297, 1352–1354.
[20] Fulda S, Jeremias I, Steiner HH, Pietsch T, and Debatin KV (1999).
Betulinic acid: a new cytotoxic agent against malignant brain-tumor
cells. Int J Cancer 82, 435–441.
[21] Tan Y, Yu R, and Pezzuto JM (2003). Betulinic acid– induced pro-
grammed cell death in human melanoma cells involves mitogen-
activated protein kinase activation. Clin Cancer Res 9, 2866–2875.
[22] Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H,
Jansen B, and Kodym R (2000). Effects of betulinic acid alone and
in combination with irradiation in human melanoma cells. J Invest
Dermatol 114, 935–940.
[23] Udeani GO, Zhao GM, Geun Shin Y, Cooke BP, Graham J, Beecher
CW, Kinghorn CW, and Pezzuto JM (1999). Pharmacokinetics and
tissue distribution of betulinic acid in CD-1 mice. Biopharm Drug Dispos
20, 379–383.
Figure 12. Effect of Bcl-2 overexpression on BetA and doxorubicin-induced
apoptosis. SHEP neuroblastoma cells transfected with vector control (circles)
or Bcl-2 (squares) were treated for 24 hours (A) or 48 hours (B) with 0 to
0.2 g/ml doxorubicin in the presence (closed symbols) or absence (open
symbols) of 5 g/ml BetA. Apoptosis was determined by FACS analysis of
DNA fragmentation of propidium iodide–stained nuclei. Note the different
y-axis scaling in (A) and (B). Mean and SD of triplicates are shown; similar
results were obtained from three independent experiments.
170 Cooperation of Betulinic Acid and Anticancer Drugs Fulda and Debatin
Neoplasia . Vol. 7, No. 2, 2005
